Immune Checkpoint Inhibitors in BRAF-Mutated Advanced Colorectal Cancer

References

• Biller LH , NgK. Pioneering a new care model for young-onset colorectal cancer: innovations in clinical care and scientific discovery. Colorectal Cancer9(3), CRC18 (2020).
   Web of Science ®Google Scholar
• Baidoun F , ElshiwyK, ElkeraieYet al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr. Drug Targets22(9), 998–1009 (2021).
   PubMed Web of Science ®Google Scholar
• Caputo F , SantiniC, BardasiCet al. BRAF-mutated colorectal cancer: clinical and molecular insights. Int. J. Mol. Sci.20(21), 5369 (2019).
   PubMed Web of Science ®Google Scholar
• Guinney J , DienstmannR, WangXet al. The consensus molecular subtypes of colorectal cancer. Nat. Med.21(11), 1350–1356 (2015).
   PubMed Web of Science ®Google Scholar
• Cunningham JM , KimCY, ChristensenERet al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am. J. Hum. Genet.69(4), 780–790 (2001).
   PubMed Web of Science ®Google Scholar
• Rajagopalan H , BardelliA, LengauerC, KinzlerKW, VogelsteinB, VelculescuVE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature418(6901), 934 (2002).
   PubMed Web of Science ®Google Scholar
• Wang L , CunninghamJM, WintersJLet al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res.63(17), 5209–5212 (2003).
   PubMed Web of Science ®Google Scholar
• Cantwell-Dorris ER , O'LearyJJ, SheilsOM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther.10(3), 385–394 (2011).
   PubMed Web of Science ®Google Scholar
• Venderbosch S , NagtegaalID, MaughanTSet al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res.20(20), 5322–5330 (2014).
   PubMed Web of Science ®Google Scholar
• Molina-Cerrillo J , SanRomán M, PozasJet al. BRAF mutated colorectal cancer: new treatment approaches. Cancers (Basel).12(6), 1571 (2020).
   PubMed Web of Science ®Google Scholar
• Luu L-J , PriceTJ. BRAF mutation and its importance in colorectal cancerIntechOpen (2019). www.intechopen.com/chapters/64803
   Google Scholar
• Grassi E , CorbelliJ, PapianiG, BarberaMA, GazzaneoF, TamberiS. Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer. Front. Oncol.11 (2021). 10.3389/fonc.2021.601722
   Google Scholar
• Tosi F , MagniE, AmatuAet al. Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis. Clin. Colorectal Cancer.16(3), e153–e163 (2017).
   PubMed Web of Science ®Google Scholar
• Schirripa M , BergamoF, CremoliniCet al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br. J. Cancer112(12), 1921–1928 (2015).
   PubMed Web of Science ®Google Scholar
• Corcoran R , GiannakisM, AllenJet al. SO-26 clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann. Oncol.31, S226–S227 (2020).
   Web of Science ®Google Scholar
• Mauri G , BonazzinaE, AmatuAet al. The evolutionary landscape of treatment for BRAFV600E mutant metastatic colorectal cancer. Cancers (Basel)13(1), 137 (2021).
   PubMed Web of Science ®Google Scholar
• Grothey A , FakihM, TaberneroJ. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann. Oncol.32(8), 959–967 (2021).
   PubMed Web of Science ®Google Scholar
• Tabernero J , GrotheyA, Van CutsemEet al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol.39(4), 273–284 (2021).
   PubMed Web of Science ®Google Scholar
• Heinzerling L , de ToniEN, SchettGet al. Checkpoint Inhibitors. Dtsch Arztebl Int.116(8), 119–126 (2019).
   PubMed Web of Science ®Google Scholar
• Franzin R , NettiGS, SpadaccinoFet al. The Use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front. Immunol. 11 (2020). 10.3389/fimmu.2020.574271
   Web of Science ®Google Scholar
• Overman MJ , McDermottR, LeachJLet al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. Lancet Oncol.18(9), 1182–1191 (2017).
   PubMed Web of Science ®Google Scholar
• Sehdev A , CramerHM, IbrahimAA, YoungerAE, O'NeilBH. Pathological complete response with Anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Discov. Med.21(117), 341–347 (2016).
   PubMed Web of Science ®Google Scholar
• Fujiyoshi K , YamamotoG, TakenoyaTet al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res.37(1), 239–247 (2017).
   PubMed Web of Science ®Google Scholar
• Pietrantonio F , OddoD, GloghiniAet al. MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer. Cancer Discov.6(9), 963–971 (2016).
   PubMed Web of Science ®Google Scholar
• Ros J , ElezE. Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. Eur. J. Cancer.172, 326–328 (2022).
   PubMed Web of Science ®Google Scholar
• Ros J , Rodríguez-CastellsM, SaoudiNet al. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. Expert Rev. Anticancer Ther.23(8), 797–806 (2023).
   PubMed Web of Science ®Google Scholar
• Cen S , LiuK, ZhengYet al. BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer. Front. Cell. Dev. Biol.9, 705060 (2021).
   PubMed Web of Science ®Google Scholar
• Tan E , SahinIH. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Expert Rev. Gastroenterol. Hepatol.15(7), 735–742 (2021).
   PubMed Web of Science ®Google Scholar
• Overman MJ , LonardiS, WongKYMet al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol.36(8), 773–779 (2018).
   PubMed Web of Science ®Google Scholar
• ndre T , ShiuKK, KimTWet al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N.Engl.J.Med.383(23), 2207–2218 (2020).
   PubMed Web of Science ®Google Scholar
• Park R , LopesL, LeeS, RianoI, SaeedA. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol.17(31), 4221–4231 (2021).
   PubMed Web of Science ®Google Scholar
• Frederick DT , PirisA, CogdillAPet al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res.19(5), 1225–1231 (2013).
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research . LAG3-PD-1 combo impresses in melanoma. Cancer Discov.11(7), 1605–1606 (2021).
   Web of Science ®Google Scholar
• Yu X , HuangX, ChenXet al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs.11(6), 1139–1148 (2019).
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. MD Anderson Cancer Center . Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X). https://clinicaltrials.gov/ct2/show/NCT04017650
   Google Scholar
• Elez E , RosJ, TaberneroJ. Seeking therapeutic synergy in BRAF mutant colorectal cancer. Nat Med.29(2), 307–308 (2023).
   PubMed Web of Science ®Google Scholar
• Tian J , ChenJH, ChaoSXet al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med.29(2), 458–466 (2023).
   PubMed Web of Science ®Google Scholar
• Fukuoka S , HaraH, TakahashiNet al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol.38(18), 2053–2061 (2020).
   PubMed Web of Science ®Google Scholar
• Ros J , BaraibarI, SaoudiNet al. Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers. Cancers (Basel)15(17), 4245 (2023).
   PubMed Web of Science ®Google Scholar
• Elez E , RosJ, FernándezJet al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat. Med.28(10), 2162–2170 (2022).
   PubMed Web of Science ®Google Scholar
• Loupakis F , IntiniR, CremoliniCet al. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the “BRAF BeCool” study. Eur. J. Cancer118, 121–130 (2019).
   PubMed Web of Science ®Google Scholar
• Ros J , MatitoJ, VillacampaGet al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann. Oncol.34(6), 543–552 (2023).
   PubMed Web of Science ®Google Scholar
• Morris VK , ParseghianCM, EscanoMet al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J. Clin. Oncol.40(Suppl. 4), 12 (2022).
   PubMedGoogle Scholar
• clinicaltrials.gov. Pfizer . A phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer. https://clinicaltrials.gov/ct2/show/NCT05217446
   Google Scholar
• Barras D , MissiagliaE, WirapatiPet al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin. Cancer Res.23(1), 104–115 (2017).
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Corcoran RB . A phase 2 study of dabrafenib and trametinib in combination with PDR001 in patients with BRAFV600E metastatic colorectal cancer. https://clinicaltrials.gov/ct2/show/NCT03668431
   Google Scholar